Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P24903
UPID:
CP2F1_HUMAN
Alternative names:
CYPIIF1
Alternative UPACC:
P24903; A7KAU6; A7KAU7; A7KAU8; A7KAU9; A7KAV0; Q32MN5; Q8WWJ2
Background:
Cytochrome P450 2F1, alternatively known as CYPIIF1, plays a crucial role in the metabolism of pneumotoxicants, including naphthalene. It exhibits the ability to dealkylate ethoxycoumarin, propoxycoumarin, and pentoxyresorufin, highlighting its significance in bioactivation processes. Notably, it bioactivates 3-methylindole (3MI) into a potentially harmful electrophile, 3-methylene-indolenine, indicating its involvement in complex metabolic pathways.
Therapeutic significance:
Understanding the role of Cytochrome P450 2F1 could open doors to potential therapeutic strategies. Its involvement in the metabolism of toxic compounds and bioactivation processes presents an opportunity for developing interventions that could mitigate the effects of pneumotoxicants and other harmful substances.